MBX Biosciences, Inc.
MBXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. With a market capitalization of $1.52B, it sits in small-cap territory. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Market Cap
$1.52B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-8.09
EPS (TTM)
$-2.17
EPS (Fwd)
$-3.94
ROE
-25.7%
ROA
-17.7%
Cash
$440.0M
Total Debt
$555,000
Free CF
-$52.5M
52W Change
156.8%
Annual Financials
Cash vs Debt
With $440.0M in cash and $555K in debt, MBX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$52.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -25.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, MBX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MBX.